Saito et al. [45] demonstrated that blocking IL-6 signaling with tocilizumab, a monoclonal antibody targeting the IL-6 receptor, significantly reduced disease activity and improved clinical outcomes in RA patients. The gene discussed is IL6; the disease is rheumatoid arthritis.